1990
|
• |
Research began at the St. Boniface General Hospital, Winnipeg, Manitoba.
 |
1999 |
• |
Monteris Medical founded.
|
2003 |
• |
“Proof of concept” prototypes completed.
|
2005 |
• |
Fully operational, integrated prototype system successfully passed evaluation tests.
|
|
• |
In vivo tests using swine demonstrated system capability for lesion size, shape and boundary control.
|
2006 |
• |
In vivo swine studies. Refined system and procedure parameters. Evaluated thermal characteristics of brain tissue.
|
2007 |
• |
Preclinical Study. Demonstrated safety and efficacy in treating canine subjects having brain tumors.
|
| 2008 |
• |
First-in-Man Phase 1 Clinical Study.* Multi-center clinical study under FDA Investigational Device Exemption. The study is designed to demonstrate capability to safely treat patients with recurrent glioblastoma multiforme brain tumors.
|
| 2009 |
• |
FDA grants 510(k) clearance for AutoLITT® system.
|
| |
• |
First-in-Man Clinical Study completes enrollment.
|
| 2010 |
• |
AutoLITT used in first commercial treatment at Barnes-Jewish Hospital.
|
|
|
|
Brain Cancer
